LCAR-AIO Cells
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 15/100
15
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Lymphocytic Leukemia
Conditions
Acute Lymphocytic Leukemia
Trial Timeline
Mar 14, 2022 → Mar 31, 2025
NCT ID
NCT05292898About LCAR-AIO Cells
LCAR-AIO Cells is a phase 1 stage product being developed by Legend Biotech for Acute Lymphocytic Leukemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT05292898. Target conditions include Acute Lymphocytic Leukemia.
What happened to similar drugs?
20 of 20 similar drugs in Acute Lymphocytic Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
6
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05292898 | Phase 1 | Terminated |
Competing Products
20 competing products in Acute Lymphocytic Leukemia